Market Cap
US$481.0m
Last Updated
2021/01/22 01:10 UTC
Data Sources
Company Financials +
Executive Summary
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. More Details
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has IVERIC bio's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ISEE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ISEE's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
-9.1%
ISEE
0.7%
US Biotechs
1.4%
US Market
1 Year Return
-20.3%
ISEE
40.9%
US Biotechs
22.6%
US Market
Return vs Industry: ISEE underperformed the US Biotechs industry which returned 41.5% over the past year.
Return vs Market: ISEE underperformed the US Market which returned 22.8% over the past year.
Shareholder returns
| ISEE | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.1% | 0.7% | 1.4% |
| 30 Day | -23.0% | 5.2% | 4.9% |
| 90 Day | -10.5% | 23.7% | 14.6% |
| 1 Year | -20.3%-20.3% | 43.2%40.9% | 25.4%22.6% |
| 3 Year | 76.6%76.6% | 27.1%20.5% | 46.8%37.0% |
| 5 Year | -89.9%-89.9% | 58.4%46.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is IVERIC bio's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
We Think IVERIC bio (NASDAQ:ISEE) Can Afford To Drive Business Growth3 months ago | Simply Wall St
How Much Are IVERIC bio, Inc. (NASDAQ:ISEE) Insiders Spending On Buying Shares?7 months ago | Simply Wall St
How Many IVERIC bio, Inc. (NASDAQ:ISEE) Shares Do Institutions Own?Valuation
Is IVERIC bio undervalued compared to its fair value and its price relative to the market?
2.24x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ISEE ($5.37) is trading above our estimate of fair value ($4.78)
Significantly Below Fair Value: ISEE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ISEE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ISEE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ISEE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ISEE is good value based on its PB Ratio (2.2x) compared to the US Biotechs industry average (4.5x).
Next Steps
Future Growth
How is IVERIC bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
20.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ISEE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ISEE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ISEE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ISEE's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ISEE's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ISEE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has IVERIC bio performed over the past 5 years?
29.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ISEE is currently unprofitable.
Growing Profit Margin: ISEE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ISEE is unprofitable, but has reduced losses over the past 5 years at a rate of 29.5% per year.
Accelerating Growth: Unable to compare ISEE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ISEE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ISEE has a negative Return on Equity (-35.69%), as it is currently unprofitable.
Next Steps
Financial Health
How is IVERIC bio's financial position?
Financial Position Analysis
Short Term Liabilities: ISEE's short term assets ($234.4M) exceed its short term liabilities ($19.9M).
Long Term Liabilities: ISEE's short term assets ($234.4M) exceed its long term liabilities ($76.0K).
Debt to Equity History and Analysis
Debt Level: ISEE is debt free.
Reducing Debt: ISEE has no debt compared to 5 years ago when its debt to equity ratio was 151.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ISEE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ISEE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 13.2% each year
Next Steps
Dividend
What is IVERIC bio current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ISEE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ISEE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ISEE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ISEE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ISEE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.6yrs
Average management tenure
CEO
Glenn Sblendorio (64 yo)
3.5yrs
Tenure
US$2,462,148
Compensation
Mr. Glenn P. Sblendorio, M.B.A., has been the President of IVERIC bio, Inc. (formerly known as Ophthotech Corporation) since February 1, 2017 and has been its Chief Executive Officer since July 1, 2017. Mr...
CEO Compensation Analysis
Compensation vs Market: Glenn's total compensation ($USD2.46M) is above average for companies of similar size in the US market ($USD1.64M).
Compensation vs Earnings: Glenn's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 14yrs | US$1.81m | 0.078% $ 376.5k | |
| CEO, President & Director | 3.5yrs | US$2.46m | 0.31% $ 1.5m | |
| Senior VP | 3.75yrs | US$1.44m | 0.089% $ 430.5k | |
| Senior VP & COO | 4yrs | US$1.43m | 0.097% $ 464.3k | |
| Co-Founder and Consultant | 14yrs | no data | no data | |
| Chief Scientific Officer | 1.25yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP | 2.92yrs | no data | no data | |
| Senior VP & Chief Human Resources Officer | 3yrs | no data | no data | |
| Senior VP & Chief Clinical Operations Officer | 5yrs | US$411.67k | no data | |
| Senior VP & Chief Medical Officer | 4.75yrs | no data | no data | |
| Chief Strategist of Gene Therapy | 1.17yrs | no data | no data |
3.6yrs
Average Tenure
59yo
Average Age
Experienced Management: ISEE's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 14yrs | US$1.81m | 0.078% $ 376.5k | |
| CEO, President & Director | 3.5yrs | US$2.46m | 0.31% $ 1.5m | |
| Independent Director | 13.42yrs | US$79.53k | 0% $ 0 | |
| Lead Independent Director | 1.25yrs | US$87.66k | 0% $ 0 | |
| Director | 0.50yr | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | US$110.93k | 0% $ 0 | |
| Independent Director | 3yrs | US$98.91k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.0yrs
Average Tenure
61yo
Average Age
Experienced Board: ISEE's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 87.1%.
Top Shareholders
Company Information
IVERIC bio, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IVERIC bio, Inc.
- Ticker: ISEE
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$480.978m
- Shares outstanding: 89.57m
- Website: https://ivericbio.com
Number of Employees
Location
- IVERIC bio, Inc.
- One Penn Plaza
- 35th Floor
- New York
- New York
- 10119
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ISEE | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Sep 2013 |
| O2T | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Sep 2013 |
Biography
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 01:10 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.